Methotrexaat Nordic (Methotrexate)

Methotrexate works by blocking the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition limits the proliferation of rapidly dividing cells, such as activated immune cells and cancerous lymphocytes, providing both immunosuppressive and cytotoxic effects.

The dose of Methotrexaat Nordic is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. No fixed regimen can be stated; the prescriber sets the appropriate dosage and schedule.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also generally avoided during breastfeeding, as it may be secreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception.

To order Methotrexaat Nordic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate is a conventional disease‑modifying antirheumatic drug (DMARD) and differs from biologic agents such as TNF‑alpha inhibitors. Compared with biologics, methotrexate is less expensive, administered by injection or orally, and has a well‑established safety profile, though it may require more laboratory monitoring. Choice depends on disease severity, patient preference and response to therapy.

Methotrexaat Nordic should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Methotrexaat Nordic is supplied for subcutaneous injection. The injection is typically given into the abdomen or thigh using a sterile needle, following aseptic technique. Patients or healthcare professionals should rotate injection sites and follow the prescriber’s instructions regarding dose volume and frequency.

The most serious risks include severe bone‑marrow suppression leading to infection, pulmonary toxicity such as interstitial pneumonitis, and progressive liver damage that can evolve to fibrosis or cirrhosis. Prompt reporting of fever, persistent cough, jaundice, or unusual bruising to a healthcare provider is essential.

Methotrexaat Nordic should not be used by individuals who are pregnant, planning pregnancy, or breastfeeding, as well as patients with severe renal or hepatic impairment, uncontrolled infections, or known hypersensitivity to methotrexate or any excipients in the formulation.